Tirzepatide Side Effects vs Semaglutide vs Retatrutide: Which Has Fewest?

With three generations of GLP-1-based medications available or in development — semaglutide (single GLP-1), tirzepatide (dual GIP/GLP-1), and retatrutide (triple GIP/GLP-1/glucagon) — patients and providers increasingly want to know: which one has the fewest side effects? This evidence-based comparison draws from clinical trial data to help you understand the trade-offs.

The Three Medications at a Glance

Semaglutide (Ozempic/Wegovy)

Semaglutide is a pure GLP-1 receptor agonist. It was the first GLP-1 medication to gain widespread use for weight loss (Wegovy, FDA-approved 2021). It has the most extensive real-world safety data with millions of patients treated worldwide.

• Mechanism: GLP-1 receptor agonist only
• Weight loss: ~15-17% body weight at 68 weeks (STEP trials)
• Maximum dose: 2.4mg weekly
• Key advantage: Most safety data, widest availability

Tirzepatide (Mounjaro/Zepbound)

Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates two gut hormone receptors simultaneously. This dual mechanism appears to provide enhanced weight loss with a side effect profile that is comparable to — and in some measures slightly better than — semaglutide.

• Mechanism: Dual GIP + GLP-1 receptor agonist
• Weight loss: ~21-22.5% body weight at 72 weeks (SURMOUNT trials)
• Maximum dose: 15mg weekly
• Key advantage: Greater weight loss, potentially better GI tolerability

Retatrutide (Investigational)

Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trial data shows remarkable weight loss potential but with a higher side effect burden at top doses. Phase 3 trials are ongoing.

• Mechanism: Triple GIP + GLP-1 + glucagon receptor agonist
• Weight loss: ~24% body weight at 48 weeks (Phase 2)
• Maximum tested dose: 12mg weekly (Phase 2)
• Key advantage: Most potent weight loss observed in trials to date

Gastrointestinal Side Effects: Head-to-Head

Nausea

• Semaglutide 2.4mg: ~44% of patients (STEP 1 trial). Typically mild-moderate. Peak occurrence during dose escalation.
• Tirzepatide 15mg: ~31% of patients (SURMOUNT-1 trial). Tends to be more episodic and shorter-lasting.
• Retatrutide 12mg: ~45-50% of patients (Phase 2). May be more intense at higher doses due to glucagon receptor activation.

Vomiting

• Semaglutide: ~24% at 2.4mg dose
• Tirzepatide: ~13% at 15mg dose
• Retatrutide: ~18-22% at 12mg dose

Diarrhea

• Semaglutide: ~30% at 2.4mg
• Tirzepatide: ~21% at 15mg
• Retatrutide: ~22-25% at 12mg

Constipation

• Semaglutide: ~24% at 2.4mg
• Tirzepatide: ~11% at 15mg
• Retatrutide: ~15% at 12mg

Discontinuation Due to GI Side Effects

This metric is arguably the most important — it tells you how many patients found side effects intolerable enough to quit:

• Semaglutide: ~5-7% discontinued due to GI adverse events
• Tirzepatide: ~4-6% discontinued due to GI adverse events
• Retatrutide: ~6-8% discontinued (Phase 2 data, higher doses)

Non-GI Side Effects Comparison

Fatigue

• Semaglutide: ~11% (vs 5% placebo)
• Tirzepatide: ~7-9%
• Retatrutide: ~10-12% (preliminary data)

Headache

• Semaglutide: ~14-18%
• Tirzepatide: ~9-12%
• Retatrutide: ~12-15%

Hair Loss

• Semaglutide: ~3-5% (likely correlated with degree of weight loss)
• Tirzepatide: ~5-6% (higher weight loss may contribute to higher rate)
• Retatrutide: ~5-8% (highest weight loss, potentially highest hair loss rate)

Injection Site Reactions

• Semaglutide: ~3-5%
• Tirzepatide: ~3-7%
• Retatrutide: ~5-8%

Serious Side Effects and Safety Signals

Pancreatitis

All three medications carry a theoretical risk of pancreatitis, though rates are very low (less than 0.5% across all clinical trials). Current data does not show meaningful differences between the three medications for pancreatitis risk.

Gallbladder Events

Gallbladder problems (gallstones, cholecystitis) are associated with rapid weight loss rather than the specific medication. Higher weight loss percentages correlate with higher gallbladder event rates, meaning retatrutide may carry the highest risk simply because it produces the most weight loss.

Thyroid Concerns

All GLP-1 agonists carry a boxed warning about medullary thyroid carcinoma risk based on animal studies. This risk has not been confirmed in humans. Patients with personal or family history of medullary thyroid cancer or MEN2 syndrome should not use these medications.

Why Tirzepatide May Have Better GI Tolerability

The clinical data consistently shows tirzepatide produces slightly lower rates of several GI side effects compared to semaglutide, despite achieving greater weight loss. The leading theory involves the GIP component:

• GIP dampens nausea: GIP receptor activation may partially counteract the nausea-inducing effects of GLP-1 receptor activation in the brainstem
• Different gastric emptying kinetics: The dual mechanism may slow gastric emptying through a different pattern than pure GLP-1 agonism, reducing the "food sitting in stomach" sensation
• Improved insulin response: GIP enhances insulin secretion in a glucose-dependent manner, potentially reducing blood sugar fluctuations that contribute to nausea and headaches

The Retatrutide Trade-Off

Retatrutide produces the most dramatic weight loss results seen in any clinical trial to date — approximately 24% body weight at 48 weeks. However, the glucagon receptor component adds additional metabolic effects that can increase side effects:

• Glucagon increases hepatic glucose output — may cause blood sugar variability and associated nausea
• Glucagon has thermogenic effects — may contribute to night sweats, increased heart rate, and feelings of warmth
• Triple receptor activation creates a more complex GI response, potentially increasing GI symptom variability

Whether the additional weight loss justifies the potentially higher side effect burden is an individual decision best made with your provider once Phase 3 data is available and the medication receives FDA review.

Choosing Based on Side Effect Profile

While no medication is universally "better" for side effects, here are general guidelines:

• If you are sensitive to nausea: Tirzepatide may be worth trying first, given its lower nausea and vomiting rates
• If you want the most safety data: Semaglutide has the longest track record and the most real-world evidence
• If constipation is a concern: Tirzepatide has notably lower constipation rates
• If you need maximum weight loss: Discuss tirzepatide (available) or retatrutide (future) with your provider, understanding the potential for more side effects with greater efficacy
• If one medication is intolerable: Switching to a different one is a viable and commonly successful strategy

Key Takeaways

• Tirzepatide shows the lowest rates of nausea, vomiting, and constipation among the three medications, despite greater weight loss than semaglutide
• Semaglutide has the most extensive safety data from real-world use
• Retatrutide produces the most weight loss but has higher GI side effect rates at top doses
• All three medications have similar serious adverse event rates (pancreatitis, gallbladder)
• Side effect differences are modest — individual variation matters more than medication choice
• Switching medications is a valid strategy if one is not well-tolerated